Pα+ March 2026 Psychedelic Bill Roundup

With 11 new bills introduced across 7 jurisdictions and significant movement on dozens of existing measures, March added to a record-setting year for U.S. psychedelic policy reform. Combined with the activity we covered in January and February, the 2026 legislative period now encompasses more than 100 bills across 35 states.

Perhaps the most significant recent development came not from a new bill, but a progress update on an existing programme announced right as March came to a close. On March 31st, Texas Lt. Governor Dan Patrick and House Speaker Dustin Burrows released a joint statement announcing that the state would be moving forward with its $50 million ibogaine research programme. (Some advocates later said that the state is committing to a full $100 million, even.)

However, unlike what lawmakers had originally envisioned in SB 2308, this progress will be led exclusively by in-state medical research teams as the state’s Health and Human Services Commission says that no drug developer has submitted a suitable proposal (we discussed many of SB 2308’s potential hurdles in our May 2025 analysis: Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials?).

Significantly, the announcement’s implications appear to extend well beyond Texas’ borders. On March 26th, Mississippi saw HB314 signed into law, a bill that explicitly requires its research consortium to coordinate with and use the same drug developer as the lead consortium in another state. These provisions seem to effectively tether the state to the Texas-anchored multistate research network. With Texas now pivoting to in-state efforts, the implications for Mississippi and other states pursuing this consortium framework, including Kentucky, Oklahoma, Missouri, and Tennessee, remain to be seen.

That said, March demonstrated that ibogaine’s broader legislative momentum remains strong. As is outlined in this roundup, by month-end, Mississippi signed its ibogaine clinical trial act into law, Kentucky’s $21 million ibogaine research fund cleared key legislative hurdles, and bills in each of Colorado, Louisiana, Georgia and Tennessee. However, West Virginia's ibogaine research bill, HB4626, which was sent to the Governor on March 31st, was subsequently vetoed.

Elsewhere, the growing trigger law movement continued to gain significant ground in states such as South Dakota, Mississippi, and West Virginia. Meanwhile, Oregon officially signed into law substantive modifications to its flagship psilocybin program, and legislative decisions in Massachusetts signalled a potential preference for regulated access over decriminalisation.

Below, we provide a state-by-state round-up of psychedelics-related bill activity in March 2026...